| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f70fbcb50a577c8d40360fb9d9c1ad8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate |
2016-09-23^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc6660afa10fc17490c872180988f1df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f71a7b78b66e387871e028ccdaecfd34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19cd76f762ea39898d251fa7cce0ea7c |
| publicationDate |
2022-01-19^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3939606-A2 |
| titleOfInvention |
Improved methods and compounds for eliminating immune responses to therapeutic agents |
| abstract |
The invention describes kit of parts of polypeptides comprising:a) a peptide comprising :a1) an MHC class II T cell epitope or a CD1d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence,andb) a polypeptide comprising:b1) a therapeutic protein andb2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1).The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein. |
| priorityDate |
2015-09-25^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |